Hemispherx says FDA rejects fatigue drug application

(Reuters) - Hemispherx Biopharma Inc said U.S. regulators had declined to approve its new drug application for Ampligen, its experimental drug for treating chronic fatigue syndrome, five years after the company first filed for the drug's approval.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news